[1]周 翔,顾 达,童 聪,等.鳖甲煎丸对CCl4诱导小鼠肝纤维化的治疗作用机制研究[J].陕西中医,2022,(2):151-156.[doi:DOI:10.3969/j.issn.1000-7369.2022.02.003]
　ZHOU Xiang,GU Da,TONG Cong,et al.Therapeutic mechanism of Biejiajian pills on mice model of liver fibrosis induced by CCl4[J].,2022,(2):151-156.[doi:DOI:10.3969/j.issn.1000-7369.2022.02.003]
点击复制

鳖甲煎丸对CCl4诱导小鼠肝纤维化的治疗作用机制研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2022年2期
页码:
151-156
栏目:
基础研究
出版日期:
2022-02-05

文章信息/Info

Title:
Therapeutic mechanism of Biejiajian pills on mice model of liver fibrosis induced by CCl4
作者:
周 翔1; 2; 顾 达2; 童 聪2; 曾佳慧2; 吴泓飞3; 赵祥安4
(1.如皋市中医院,江苏 南通 223001; 2.扬州大学,江苏 扬州 225009; 3.南京医科大学,江苏 南京 210000; 4.扬州大学临床医学院,江苏 扬州 225009)
Author(s):
ZHOU Xiang; GU Da; TONG Cong; ZENG Jiahui; WU Hongfei; ZHAO Xiang'an
(Rugao Hospital of Chinese Traditional Medicine,Nantong 223001,China)
关键词:
肝纤维化;  鳖甲煎丸;  单核细胞;  单核细胞趋化因子1;  肿瘤坏死因子-α;  转化生长因子β1
Keywords:
Liver fibrosis;  Biejiajian pills;  Monocyte;  MCP-1;  TNF-α;  TGF-β1
分类号:
R 657.31
DOI:
DOI:10.3969/j.issn.1000-7369.2022.02.003
文献标志码:
A
摘要:
目的:研究鳖甲煎丸是否可以通过抑制单核细胞浸润从而减少单核细胞相关的促炎促纤维化细胞因子分泌来缓解肝纤维化。方法:40只小鼠被随机分为五组:空白对照组、四氯化碳(CCl4)组、低剂量鳖甲煎丸组、中剂量鳖甲煎丸组和高剂量鳖甲煎丸组。其中CCl4组和鳖甲煎丸组予以CCl4腹腔注射,每周两次,连续4周。高、中、低剂量鳖甲煎丸组小鼠在予以CCl4腹腔注射的同时,分别每日予以鳖甲煎丸灌胃,连续4周,剂量为2.2、1.1、0.55 g /(kg·d)。实验结束后,通过肝酶、HE染色检测肝脏炎症,Masson染色、α-SMA和Col-I免疫组化观察肝脏胶原沉积和HSCs活化,CD11b和F4/80免疫组化、流式细胞术观察肝脏中单核细胞数量,qRT-PCR和WB检测肝脏中单核细胞趋化因子-1(MCP-1)的表达。结果:经4周CCl4腹腔反复注射后,小鼠肝酶谷丙转氨酶(ALT)、谷草转氨酶(AST)明显升高,HE染色显示肝脏肝细胞坏死、炎性细胞浸润、胶原沉积,提示纤维化模型小鼠建立成功。鳖甲煎丸给药后,纤维化模型小鼠肝脏炎症和纤维化明显减少。与CCl4组比较,鳖甲煎丸组小鼠单核细胞的肝内浸润明显减少。同时,鳖甲煎丸显著降低单核细胞相关促炎性和促纤维化细胞因子分泌,与肝内单核细胞数量减少相一致。进一步的研究发现鳖甲煎丸能够降低肝组织损伤时MCP-1分泌,表明鳖甲煎丸可以减少肝纤维化过程中单核细胞的浸润。结论:鳖甲煎丸可通过抑制单核浸润缓解肝纤维化,提示鳖甲煎丸可以作为预防和治疗肝纤维化的候选药物。
Abstract:
Objective:To investigate whether Biejiajian pills(BJJP)can alleviate liver fibrosis by inhibiting monocyte infiltration and thereby reducing monocytes-related pro-inflammatory and pro-fibrotic cytokine secretion.Methods:Forty mice were randomly divided into five groups:blank group,CCl4 group,low-dose BJJP group,middle-dose BJJP group and high-dose BJJP group.CCl4 group and BJJP group were given intraperitoneal injection of CCl4 twice a week for four weeks.Otherwise,the mice in high,middle and low-dose BJJP groups were given BJJP by gavage every day for four consecutive weeks at doses of 2.2,1.1 and 0.55 g/(kg·d).At the end of the experiment,liver inflammation was detected by liver enzyme and HE staining,and liver collagen deposition and HSCs activation were observed by Masson staining,α-SMA and Col-I immunohistochemistry.The number of monocytes in the liver was observed by CD11b and F4/80 immunohistochemistry,flow cytometry.And monocyte chemotactic protein-1(MCP-1)expression in the liver was detected by qRT-PCR and WB.Results:After repeated-CCl4 injection intraperitoneally for 4 weeks,liver enzymes ALT and AST in the mice increased significantly.HE staining showed hepatocyte necrosis,leucocytes infiltration and collagen deposition in the liver,suggesting that fibrosis model was successfully established.After BJJP administration,liver inflammation and fibrosis significantly reduced when compared with CCl4 group.Meanwhile,the intrahepatic infiltration of monocytes in BJJP group was significantly decreased.BJJP also significantly reduced monocytes-related proinflammatory and fibrogenic cytokines secretion,which was consistent with the decrease of monocytes infiltration.Further study found that BJJP can reduce MCP-1 secretion in liver tissue,which explains why BJJP can reduce monocytes infiltration during the liver fibrosis.Conclusion:BJJP can alleviate liver fibrosis by inhibiting monocytes infiltration.These results suggestted that BJJP can be used as a candidate drug for the prevention and treatment of liver fibrosis.

参考文献/References:

[1] Cordero EL,Huch M.The balancing act of the liver:Tissue regeneration versus fibrosis[J].Journal of Clinical Investigation,2018,128(1):85-96.
[2] Sumeet KA,Harshad D,John E,et al.Burden of liver diseases in the world[J].Journal of Hepatology,2019,70(1):151-171.
[3] Pradere JP,Kluwe J,De Minicis S,et al.Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice[J].Hepatology,2013,58(4):1461-1473.
[4] Karlmark KR,Weiskirchen R,Zimmermann HW,et al.Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis[J].Hepatology,2009,50(1):261-274.
[5] Krenkel O,Puengel T,Govaere O,et al.Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis[J].Hepatology,2018,67(4):1270-1283.
[6] Baeck C,Wei X,Bartneck M,et al.Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 accelerates liver fibrosis regression by suppressing Ly6C(+)macrophage infiltration in mice[J].Hepatology,2014,59(3):1060-1072.
[7] 赵治友,姚真敏,钟庆平,等.中药鳖甲煎丸抗肝纤维化作用的临床研究[J].中西医结合肝病杂志,2001,11(3):136.
[8] 陈松林,林英辉,杨德芬,等.鳖甲煎丸对瘀血阻络型慢性乙型肝炎患者外周血Th17细胞表达水平的影响[J].中医药导报,2016,22(4):24-26.
[9] 李映智.肝纤维化辨治体会[J].陕西中医,2012,33(6):767-768.
[10] 汪晓军,张奉学,郭兴伯.肝星状细胞,机体血浆纤溶系统与活血化瘀法[J].中西医结合肝病杂志,2002,12(6):383-384.
[11] Ala A,Dhillon AP,Hodgson HJ.Role of cell adhesion molecules in leukocyte recruitment in the liver and gut[J].International Journal of Experimental Pathology,2010,84(1):151-171.
[12] 吴明兵,张文锋,龚建平,等.渥曼青霉素通过Chemerin/CMKLR1途径抑制Kupffer细胞NLRP3的活性缓解小鼠非酒精性脂肪肝[J].重庆医学,2018,47(17):2279-2284.
[13] 艾丁丁,罗伟生,蒋云霞.动物肝纤维化模型建立研究进展[J],陕西医学杂志,2020,49(8):907-909.
[14] Evaggelia L,Henning WZ,Kit L,et al.Monocyte subsets in human liver disease show distinct phenotypic and functional characteristics[J].Hepatology,2013,57(1):385-398.
[15] Secco D,Wang J,Zeng Z,et al.A dynamic spectrum of monocytes arising from the in situ reprogramming of CCR2+ monocytes at a site of sterile injury[J].The Journal of Experimental Medicine,2015,212(4):447-456.
[16] Antonella P,Prakash R,John PI,et al.Liver fibrosis and repair:Immune regulation of wound healing in a solid organ[J].Immunology,2014,14(3):181-194.
[17] Ramon B,David AB.Liver fibrosis[J].The Journal of Clinical Investigation,2005,115(2):209-218.
[18] Ralf W,Frank T.Liver fibrosis:From pathogenesis to novel therapies[J].Dig Dis,2016,34(4):410-422.
[19] 汪慧兰.恩替卡韦联合鳖甲煎丸治疗乙肝肝硬化失代偿临床疗效[J].临床医药文献电子杂志,2019,6(38):62-63.
[20] 许世申.鳖甲煎丸联合恩替卡韦胶囊治疗乙肝肝硬化肝功能代偿期的效果观察[J].临床医学工程,2019,26(1):83-84.
[21] 徐志刚,曹 罡,程传涛,等.CTRP3通过TGF-β1/Smad信号通路减弱肝星状细胞活性机制研究[J].陕西医学杂志,2020,49(5):523-526.
[22] Katherine J,Ian NC.Infiltrating monocytes in liver injury and repair[J].Clin Transl Immunology,2016,5(11):113.
[23] 张婷婷.人血管内皮细胞氚水暴露后差异表达基因的筛选及毒性效应研究ICOSL/ICOS调控HSCs活化相关信号通路介导日本血吸虫感染小鼠肝纤维化的分子机制[D].苏州:苏州大学,2018.
[24] 梁 松,王 波,许 静,等.ICOS转基因小鼠感染日本血吸虫后HSCs活化效应及对肝纤维化的影响[J].中国人兽共患病学报,2014,30(11):1103-1109.
[25] 胡爱荣,丁一生,程明亮.丹芍化纤胶囊对大鼠肝纤维化的预防作用及对HSCs增殖和活化的影响[J].中医药学刊,2006,24(11):2112-2114.
[26] 宁佐伟,张文雍,李 洋,等.血管紧张素(1-7)对胆管结扎诱导的肝纤维化大鼠肝窦血管生成的抑制作用[J].中华肝脏病杂志,2013,21(12):907-913.
[27] Josef E,Matthias B,Xiao W,et al.CCl2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis[J].Gut,2014,63(12):1960-1971.
[28] John WH,Jan KD,Zbigniew K,et al.Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCl2[J].Journal of Hepatology,2006,44(6):1167-1174.
[29] Ekihiro S,Samuele DM,Sayaka I,et al.CCR2 promotes hepatic fibrosis in mice[J].Hepatology,2009,50(1):185-197.
[30] 韩 珍,孙焕芹,代艳超,等.慢性乙型肝炎患者血清MCP-1水平及其与肝组织炎症、纤维化的关系[J].山东医药,2015,32(1):66-67.
[31] 吴四海,黄 磊,楼 跃,等.MCP-1和MIP-2在新生鼠胆道闭锁肝内胆管损伤及肝纤维化中的作用[J].中华小儿外科杂志,2014,35(4):284-289.

相似文献/References:

[1]邱 勇.桃红四物汤对CCl4诱导肝纤维化小鼠治疗作用及其机制研究[J].陕西中医,2019,(12):1673.
　QIU Yong..Protective effects of Taohong Siwu decoction on CCl4induced hepatic fibrosis model mice[J].,2019,(2):1673.
[2]梁瀞云,唐 燕,司马玲,等.柴胡疏肝散在肝脏疾病中的应用研究进展[J].陕西中医,2022,(11):1651.[doi:DOI:10.3969/j.issn.1000-7369.2022.11.038]
　LIANG Jingyun,TANG Yan,SIMA ling,et al.Application of Chihu Shugan powder in liver diseases[J].,2022,(2):1651.[doi:DOI:10.3969/j.issn.1000-7369.2022.11.038]
[3]胡哲君,汤穆浛,张 锐,等.基于“肝病实脾”理论探讨逍遥散对肝纤维化大鼠肝星状细胞铁死亡的影响[J].陕西中医,2024,(2):159.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.003]
　HU Zhejun,TANG Muhan,ZHANG Rui,et al.Effect of Xiaoyao powder on ferroptosis of hepatic stellate cells in rats with liver fibrosis based on the theory of “treating liver by nourishing spleen”[J].,2024,(2):159.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.003]
[4]牛丽娜,窦 婧,马 燕,等.和血柔肝方通过PI3K/Akt/NF-κB信号通路调控自噬相关蛋白改善大鼠肝纤维化机制研究[J].陕西中医,2024,(2):165.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.004]
　NIU Lina,DOU Jing,MA Yan,et al.Mechanism of Hexue Rougan decoction in relieve liver fibrosis in rats by regulating autophagy-related proteins through PI3K/Akt/NF-κB signaling pathway[J].,2024,(2):165.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.004]
[5]李杳瑶,刘 华,孙铜林,等.鳖甲煎丸对肝癌大鼠黏着斑激酶/雷帕霉素靶蛋白通路的影响[J].陕西中医,2024,(3):308.[doi:DOI:10.3969/j.issn.1000-7369.2024.03.004]
　LI Yaoyao,LIU Hua,SUN Tonglin,et al.Effects of Biejia Jianwan on liver histopathological features and FAK/mTORC1 pathway in rats with hepatocellular carcinoma[J].,2024,(2):308.[doi:DOI:10.3969/j.issn.1000-7369.2024.03.004]
[6]俞佳雯,周 薏,林天龙(加拿大),等.乙肝肝纤维化中西医研究进展[J].陕西中医,2025,46(2):273.[doi:DOI:10.3969/j.issn.1000-7369.2025.02.027]
　YU Jiawen,ZHOU Yi,LIN Tianlong,et al.Progress of traditional Chinese and Western medicine research on chronic hepatitis B hepatic fibrosis[J].,2025,46(2):273.[doi:DOI:10.3969/j.issn.1000-7369.2025.02.027]

备注/Memo

备注/Memo:
基金项目:江苏省自然科学基金资助青年项目(BK20200266); 江苏省博士后科研资助项目(2021K536C)
更新日期/Last Update: 2022-02-09